AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06133972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ianalumab
Description: Ianalumab s.c. monthly Ianalumab s.c. quarterly
Study NCT05260060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Metacognitive Therapy (Group-MCT): Experimental
Description: Group metacognitive therapy (Group-MCT) focuses on developing adaptive control of worry, repetitive negative thinking and attention and modifies beliefs that maintain unhelpful thinking patterns. Treatment is 6 to 8 weekly sessions delivered by two trained mental health professionals, guided by a treatment manual, lasting approximately 90 minutes each session.
Study NCT06270186 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Type 1 myotonic dystrophy
Description: To compare classical neuropsychological test and on Good Diag NMD software in Type 1 myotonic dystrophy patients
Study NCT04868890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ampion
Description: Inhaled Ampion
Study NCT04868890 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled Placebo
Study NCT05765240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid Topical Gels
Description: Hyaluronic acid is a linear polysaccharide found naturally in different organs and tissues such as the extracellular matrix of connective tissue, synovial fluid, embryonic mesenchyme, and skin. The periodontal ligament is a key element found in periodontal tissues such as the gingiva, alveolar bone, and cementum. It plays a regulatory role in the inflammatory response, impedes the penetration of viruses and bacteria into the tissue, and is involved in inflammation, granulation tissue formation, epithelial formation, and tissue remodeling. There are no reported drug interactions or contraindications for the use of hyaluronic acid.
Study NCT05765240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode Laser Biostimulation
Description: Laser therapy can amplify wound healing by increasing cell regeneration and modulating the immune response. In animal experiments with diode laser, it was observed that postoperative low-level laser application increased wound healing. Diode laser applied at frequencies of 20 mW and 670 nm and 200 mW and 820 nm accelerated clot organization and new vessel formation after tooth extraction.
Study NCT05117320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI support
Description: Images were allocated to participants. In randomized allocation, one half of the images for each participant are viewed with AI support and the other half is viewed without AI support on the first trial day. On the second trial day the same images are viewed without versus with AI, respectively. This ensures that all images are read twice by the same participant both with and without AI support.
Study NCT04604821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Milieu Teaching
Description: A behavioral language intervention that uses naturally occurring interactions to facilitate young children's language skills.
Study NCT04604821 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parent Education
Description: Parents receive information on child developmental milestones.
Study NCT05127473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8 B, 10 mg/mL
Description: All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
Study NCT05139784 — intervention group
Intervention type: OTHER
Intervention: Biosampling
Description: Collection of blood and stool specimens; and collection of lymph node specimens for the group undergoing surgical lymphadenectomy.
Study NCT06042569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT06042569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT06042569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT06042569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV
Study NCT06042569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies
Study NCT06042569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Chart Review
Description: Ancillary studies
Study NCT06042569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06042569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05775406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-253
Description: KT-253 will be administered intravenously per the defined protocol frequency and dose level.
Study NCT06142253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WATER+CT
Description: This is an 8-month long two phase intervention. The first phase consists of 6 months of thrice weekly pool-based exercise occurring at VA Palo Alto. After completion of the 6 month long pool based exercise, participants transition to ten sessions of cognitive training that will occur over 2 months at the VA Palo Alto.
Study NCT06142253 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: This condition involves receipt of educational materials about brain health and healthy lifestyles as well as regular contact with study staff.
Study NCT04577859 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ensoETM. Esophageal cooling during AF ablation
Description: Esophageal cooling during AF ablation: The ensoETM probe is inserted via the orogastric route when the patient is under general anesthesia. The device is set to cool during ablation of the posterior aspect of the left atrium, to protect against transmitted thermal energy and so reduce or prevent esophageal thermal injury.
Study NCT04577859 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal temperature monitoring probe
Description: An esophageal temperature monitoring probe is a typical monitoring device used in standard of care AF ablations. This allows any temperature rise in the esophagus to be detected during ablation. If the temperature reaches >38 degrees then it is widely recognized that ablation should be halted until the temperatures fall back to below 38 degrees. It therefore has the ability to detect esophageal temperature rise only.
Study NCT06314373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK39775 Monotherapy
Description: HSK39775 will be administered orally once daily
Study NCT06411769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 50K4LIfe
Description: This intervention will consist of the Walking Challenge only.
Study NCT06194929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Defactinib will be administered at 200 mg twice daily orally per arm description.
Study NCT06194929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib
Description: Avutometinib will be administered at 3.2 mg twice a week orally per arm description.
Study NCT06194929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Encorafinib administered orally per arm description.
Study NCT05920343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 MG
Description: The intervention in the experimental arm will be rivaroxaban, 10 mg PO once daily (prophylactic dosing) for 180 days after the start of systemic therapy or until one of the primary study outcomes occurs (VTE or major bleeding).
Study NCT05920343 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Identical to Rivaroxaban intervention except participants will receive a matched placebo instead of the study drug
Study NCT06517888 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AAVAnc80-antiVEGF via Akouos Delivery Device
Description: AAVAnc80-antiVEGF is a sterile suspension intended to be administered via intracochlear administration as a single dose using the Akouos Delivery Device
Study NCT04733079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cleanweb electronic messaging ePro
Description: Patient and their medecin will communicate regulary via Cleanweb electronic messaging ePro to adapt the posology of THU untill the target urecemia is reached
Study NCT04733079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual follow-up
Description: Adaptation and follow-up of ULT according to referring physician's habits
Study NCT05158205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 12-week yoga intervention in which 60-minute classes are completed at Texas State University 3 times per week
Study NCT06411769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Text Messaging
Description: In this intervention, participants will received notifications onto the Pathverse app
Study NCT05158205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow, deep breathing
Description: 12-week home-based intervention in which 5 weekly 20-minute breathing sessions are completed
Study NCT05158205 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control breathing
Description: 12-week home-based intervention in which 5 weekly 20-minute breathing sessions are completed
Study NCT06210555 — intervention group
Intervention type: PROCEDURE
Intervention: Renal transplantation
Description: Operative procedure - receipt of a kidney
Study NCT06210555 — intervention group
Intervention type: PROCEDURE
Intervention: Living kidney donation
Description: Operative procedure - donation of a kidney
Study NCT05353387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational Interviewing will be carried out in 3 different sessions, each to be conducted one week apart. 6 weeks after the last interview, first follow up would be conducted through phone communication and 6 weeks after the first follow up, a face-to-face interview would be conducted for the scales to be applied to the participants again.
Study NCT04979429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perioperative Pain Self-management (PePS)
Description: 4 sessions of telephone CBT-based pain self-management.
Study NCT06054555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 206
Description: ABP 206 will be given intravenously over a period of 30 or 60 minutes, every 4 weeks (Q4W) for a total of 24 months.
Study NCT06054555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab will be given intravenously over a period of 30 or 60 minutes, Q4W for a total of 24 months.
Study NCT06257706 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Vedolizumab
Description: All participants will begin a vedolizumab induction regimen of 300 mg IV at Weeks 0, 2, 6, and 10 followed by vedolizumab 300 mg IV every 8 weeks starting at Week 14. Treatment may be modified at Weeks 22, 30, and/or 38 based on the results of the target assessment at each of these time points.
Study NCT06470048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ianalumab matching placebo subcutaneous (s.c.) injection as defined in the protocol
Study NCT06470048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ianalumab
Description: subcutaneous (s.c.) injection as defined in the protocol
Study NCT06470048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ianalumab
Description: subcutaneous (s.c.) injection as defined in the protocol
Study NCT04867187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: 20 minutes of high frequency (20Hz) rTMS.
Study NCT04867187 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: 20 minutes of high frequency (20Hz) rTMS.
Study NCT04867187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy using virtual reality
Description: active mirror-based therapy
Study NCT04867187 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mirror therapy using sham mirror
Description: 20 minutes of sham mirror-based therapy
Study NCT06550752 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: UC-MSCs and PRP
Description: UC-MSCs are progenitor cells that can differentiate into various types of cells in the body and have the ability to regenerate and repair damaged tissue. During repair and regeneration, these cells secrete expedient and powerful bioactive paracrine factors including cytokines, chemokines, collagen, fibronectin, and growth factors promoting tissue repair, angiogenesis, and the regeneration of nerve cells as well as regulating cellular pathways including immunomodulation and inflammatory responses. Additionally, PRP contains numerous growth factors and cytokines, including vascular endothelial growth factor (VEGF), transforming growth factor beta-1 and beta-2 (TGF-β1/2), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), interleukin 8 and matrix metalloproteinases 2,9. The combined effect of these factors provided by PRP injections is proposed to have anti- inflammatory, reparative, neuroprotective and neurotrophic effects that contribute to the treatment of ED.
Study NCT06411769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual
Description: In this Phase 2 individual-level intervention, participants will receive remote education modules and one-to-one monthly phone-based coaching.
Study NCT06411769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School
Description: In this Phase 2 school-level intervention, participants will receive group educational sessions, school environmental modifications (floor distance markings, signage in corridors and breakrooms, promotional items), and participate in work time/weekend group walks/hikes.
Study NCT06370182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANA Funnel Catheter
Description: Mechanical thrombectomy using a stent retriever delivered by the ANA device that enables local flow restriction when deployed.
Study NCT06370182 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Mechanical thrombectomy using a stent retriever delivered by an approved guide catheter with or without an intermediate catheter and aspiration per conventional techniques.
Study NCT04939935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Extended release metformin.
Study NCT04939935 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo is inactive tablets that is identical to the intervention Metformin tablets.
Study NCT04770402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 12 acupuncture sessions over 10 weeks
Study NCT04770402 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care CIPN management
Description: Investigator directed standard of care management of CIPN
Study NCT05854251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Subjects receive an s.c. injection of 100 mg Anakinra on the evening before and on the respective study day 60 minutes before ingestion of the mixed-meal
Study NCT05854251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.67 ml of s.c. injection of saline will be taken on the evening before and on the respective study day 60 minutes before ingestion of the mixed-meal
Study NCT06253494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdHER2DC vaccine
Description: AdHER2DC vaccine is given by intradermal injections on Day 1 of cycles 1-3 (priming) followed by optional boost doses (up to 3), on Day 1 of cycles 6, 9, 12
Study NCT06253494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is given by IV infusion on Day 8 of cycle 1 and Day 1 of cycles 2-16
Study NCT06253494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: N-803 is given by subcutaneous injections on Day 1 of cycles 1-16
Study NCT06253494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib is taken orally on Days 8-28 on cycle 1 and every day of cycles 2-16
Study NCT06253494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PATHWAY HER2 (4B5) assay
Description: Used during screening to estimate eligibility
Study NCT06429735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: N1 Implant
Description: The N1 Implant is a type of implantable brain-computer interface
Study NCT06429735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: R1 Robot
Description: The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.
Study NCT06356259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRX-010
Description: Administered IV
Study NCT06356259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT05762302 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MeMed BV test
Description: Following the MeMed BV test result, the clinician will decide whether or not to prescribe an antibiotic for your condition
Study NCT06402669 — intervention group
Intervention type: OTHER
Intervention: Packed Red Blood Cell Administration
Description: Difference in occurrence of mortality in patients transferred versus directly admitted who have packed red blood cell administration in the first four hours of arrival to the hospital.
Study NCT04811040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Lenacapavir
Description: Tablets administered without regard to food
Study NCT04811040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Lenacapavir
Description: Administered in the abdomen via subcutaneous injections
Study NCT04811040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teropavimab
Description: Administered intravenously
Study NCT04811040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinlirvimab
Description: Administered intravenously
Study NCT06106607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: A 20-week intervention with a basic part, including~1. A group session with education about IBD,physical activity and exercise in relation to IBD (definitions, evidence and recommendations). Furthermore, access to a video with general information about IBD, physical activity and exercise~2. Four individual motivational counselling sessions (two physical, two by telephone) with a project nurse. These will involve identifying individual motivation and opportunities for increasing physical activity and behavioral goal setting.~An optional intervention part will follow, including choises between (or all of)~1. A one-hour individual session with a physiotherapist, involving guidance in physical activity and exercise tailored to the individual.~2. Being teamed up with 1-2 'exercise buddies' (other participants from the overall intervention group).~3. Access to 4 short 2-3 minutes videos/'reels' of a physiotherapist explaining and demonstrating beneficial physical exercises.
Study NCT06352658 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional mandibular advancement device
Description: With a vacuum mahine (Biostar, NY) a 2-mm-thick hard, clear resin sheet was adapted to the cast. The excess material was cut, borders were trimmed and smoothed. Maxillary mandibular casts were mounted by a protrusive the interocclusal record. The appliances were re-placed on the mounted casts to be splinted to form a Monoblock MAD by autopolymerizing acrylic resin at the premolar -molar area.
Study NCT06352658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD CAM mandibular advancement device
Description: 3D models for the stone casts were constructed with laser scanning machine (accuracy \<20 µm; D500, 3shape).~Maxillary and mandibular casts were rescanned in the achieved 75% advancement position and monoblock device was designed by CAD (computer-aided design) with 3D software (3-matic; Materialise) and printed by
Study NCT06352658 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uvuloplatopharyngeoplasty UPPP
Description: uvulopalatopharyngeoplasty UPPP were performed by the same ENT surgeon under GA.
Study NCT05859412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic exercises
Description: The neurodynamic exercises will consist of a home-based exercise programme performed over a period of 6 weeks. Patients will attend a single session with an investigator who will instruct them the home exercise programme consisting of nerve and tendon gliding exercises which will be adjusted with pre-specified progressions over the 6 weeks intervention period. Patients will receive a leaflet and a video link detailing these exercises.
Study NCT05859412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid injection (Depomedrone 40mg)
Description: Steroid injection (Depomedrone 40mg) into the carpal tunnel as per standard practice in patients with carpal tunnel syndrome
Study NCT05859412 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Advice
Description: Group receiving advice but no additional treatment
Study NCT05127473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8 B, 100 mg/mL
Description: All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.